Noom Expands Blood Testing, Gene Editing Targets Cholesterol, Retro Biosciences Surges
May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes.
Today's top stories:
Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy
Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication
Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.